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Disorganized ion transport caused by hypo- or hyperfunc-
tioning of the cystic fibrosis transmembrane conductance regu-
lator (CFTR) can be detrimental andmay result in life-threaten-
ing diseases such as cystic fibrosis or secretory diarrhea. Thus,
CFTR is controlled by elaborate positive and negative regula-
tions for an efficient homeostasis. It has been shown that expres-
sion and activity of CFTR can be regulated either positively or
negatively by PDZ (PSD-95/discs large/ZO-1) domain-based
adaptors. Although a positive regulation by PDZ domain-based
adaptors such as EBP50/NHERF1 is established, the mecha-
nisms for negative regulation of the CFTR by Shank2, as well as
the effects ofmultiple adaptor interactions, are not known.Here
we demonstrate a physical and physiological competition
between EBP50-CFTR and Shank2-CFTR associations and the
dynamic regulation of CFTR activity by these positive and neg-
ative interactions using the surface plasmon resonance assays
and consecutive patch clamp experiments. Furthermore
whereas EBP50 recruits a cAMP-dependent protein kinase
(PKA) complex to CFTR, Shank2was found to be physically and
functionally associated with the cyclic nucleotide phosphodies-
terase PDE4D that precludes cAMP/PKA signals in epithelial
cells andmouse brains. These findings strongly suggest that bal-
anced interactions between themembrane transporter andmul-
tiple PDZ-based adaptors play a critical role in the homeostatic
regulation of epithelial transport and possibly the membrane
transport in other tissues.
The cystic fibrosis transmembrane conductance regulator
(CFTR)2 is a Cl channel and a key regulator of fluid and ion
transport in the gastrointestinal, respiratory, and genitourinary
epithelia (1, 2). Hypofunctioning of CFTR due to genetic
defects causes cystic fibrosis, the most common lethal genetic
disease in Caucasians (3, 4), whereas hyperfunctioning of CFTR
resulting from various infections evokes secretory diarrhea (5),
the leading cause of mortality in early childhood in the world
(WorldHealthOrganization statistics). Therefore,maintaining
and regulating a dynamic balance between CFTR-activating
and CFTR-inactivating machineries is an important mecha-
nism for maintaining body homeostasis.
Accumulating evidence suggests that protein-protein inter-
actions play a critical role in the regulation of CFTR and other
epithelial transporters (6–8). PDZ (PSD-95/discs large/ZO-1)
domain-based adaptors, best studied in the postsynaptic den-
sity (PSD) region of neurons, have emerged as a large group of
proteins that sequester functionally related groups of trans-
porters, receptors, and other effector proteins into integrated
molecular complexes (9, 10). Epithelial cells also utilize specific
PDZ proteins to direct the polarized activities in their apical
and basolateral membranes. Recently we reported functional
and physical associations between the PDZ domain-containing
protein Shank2 and two epithelial transporters, CFTR and the
Na/H exchanger 3 (NHE3) (11, 12). Interestingly Shank2
attenuated the cAMP-dependent regulation of CFTR and
NHE3. Conversely it has been shown that PDZ domain-based
adaptors, such as EBP50/NHERF1 and E3KARP/NHERF2, can
enhance the effects of cAMP on these transporters by recruit-
ing a cAMP-dependent protein kinase (PKA)/PKA-anchoring
protein (AKAP) complex (13, 14). Physiological significance of
these adaptors in the regulation of CFTR function has also been
verified inmany other studies (6). For example, recent evidence
demonstrates that native CFTR and EBP50 are co-immunopre-
cipitated in human airway epithelial cells (15) and that CFTR-
dependent anion current is reduced in the intestine of EBP50
knock-out mice (6).
The PDZ domain of Shank proteins has a three-dimensional
structure very similar to the PDZ domains of EBP50/NHERF1
(16). In particular, these PDZ domains all contain a negatively
charged amino acid at the end of the  C strand of the PDZ
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domain structures (Glu43 in hEBP50, Asp634 in rShank1, and
Asp80 in hShank2) that preferentially interacts with a positively
charged residue at the 1 position in the C terminus of the
membrane transporters, such as TRL in CFTR. Therefore,
the question arises whether EBP50 and Shank2 have distinct
CFTR binding sites or mutually compete for binding of a single
site in cells expressing both adaptor proteins.
In the present study, we determined the kinetic properties
and physiological significance of the interactions between
CFTR and the PDZ-based adaptors EBP50 and Shank2. Using
surface plasmon resonance (SPR) assays, we found that the dis-
sociation constant (KD) of CFTR-Shank2 bindingwas similar to
that of CFTR-EBP50 binding and that both proteins apparently
compete for binding at the same site. Consecutive patch clamp
studies revealed that CFTR Cl channel activity was dynami-
cally regulated by the competition of Shank2 and EBP50 bind-
ing. Notably in contrast to the PKA/AKAP recruitment by
EBP50 (6), Shank2 was found to tether PDE4D to the CFTR
complex, thus attenuating cAMP/PKA signals. Our results sug-
gest that the competitive balance between Shank2 and EBP50
binding to the CFTR channel may maintain homeostatic regu-
lation of epithelial ion and fluid transport.
EXPERIMENTAL PROCEDURES
Cell Cultures and PlasmidVectors—NIH3T3 andCOS7 cells
were maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal calf serum. T84 cells were purchased
from the American Type Culture Collection (ATCC CCL-248)
and maintained in a 1:1 mixture of Ham’s F-12 medium and
Dulbecco’s modified Eagle’s medium supplemented with 5%
fetal bovine serum. CHO-K1 cells (KCLB 10061; Korea Cell
Line Bank, Seoul, Korea) were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum. The
pcDNA3.1-rShank2/CortBP1 (17), pcDNA3.1-hEBP50/NHERF-1
(12), and pCMV5 vectors containing rPDE4D1 to rPDE4D9
have been described previously (18).
SPR Measurements and Kinetic Analysis of Sensorgrams—
PDZ1-(1–139), PDZ2-(132–299), and PDZ12-(1–299)
domains of hEBP50/NHERF1 and the PDZ domain of
rShank2/CortBP1-(1–142) were PCR-amplified and cloned
into the pRSET A vector (Invitrogen) to create His-tagged
constructs. The C-terminal 29 amino acid residues of
hCFTR (GenBankTM accession number NM_000492) and
PDZ12 of hEBP50 (for competition assay, see Fig. 1D) were
PCR-amplified and cloned into the pGEX-4T-1 vector
(Amersham Biosciences) to create GST fusion constructs.
All constructs were confirmed by sequence analysis. All
fusion proteins were expressed in Escherichia coli BL21
(DE3) cells and purified on Ni2-nitrilotriacetic acid (NTA)
resin (Qiagen, Venlo, The Netherlands) and glutathione-
Sepharose 4B (Amersham Biosciences) as appropriate. The
purified proteins were quantified using Bio-Rad protein
assay reagent, and their purity was assessed as90% by Coo-
massie staining of SDS-PAGE gels. An SPR system equipped
with an NTA chip (BIAcore 3000; Biacore AB, Uppsala, Swe-
den) was used to capture His-tagged PDZ fusion proteins.
Analytes (GST-tagged proteins) at various concentrations in
HEPES-buffered saline-EP (0.01 M HEPES, 0.15 M NaCl, 50
M EDTA, 0.005% Tween 20, pH 7.4) were perfused at a flow
rate of 30 l/min. The sensor chip was regenerated between
each analysis using successive injections of solutions con-
taining 0.15 M NaCl and 0.35 M EDTA. Response curves were
generated by subtracting the background signal generated
simultaneously by the control flow cell. Background-sub-
tracted curves were prepared for fitting by subtracting the
signal generated by buffer alone on experimental flow cells.
Sensorgram curves and kinetic parameters were evaluated by
the BIAevaluation 3.1 software (Biacore AB), which uses
numerical integration algorithms.
Measurement of ClChannel Activities—Whole-cell record-
ings were performed on CFTR-transfected CHO-K1 cells as
reported previously (19). The pipette solution contained 140
mMN-methyl D-glucamine chloride (NMDG-Cl), 5 mM EGTA,
1 mMMgCl2, 1 mM Tris-ATP, and 10 mMHEPES (pH 7.2), and
the bath solution contained 140 mM N-methyl D-glucamine
chloride, 1 mM CaCl2, 1 mMMgCl2, 10 mM glucose, and 10 mM
HEPES (pH 7.4). All experiments were performed at room tem-
perature (22–25 °C). After establishing the whole-cell configu-
ration, CFTRwas activated by adding forskolin and/or 3-isobu-
tyl-1-methylxanthine (IBMX). The holding potential used was
30mV, and the current output was filtered at 5 kHz. Currents
were digitized and analyzed using an AxoScope 8.1 system and
a Digidata 1322A analog/digital converter (Axon Instruments,
Union City, CA).
Single channel activity of CFTR was measured in inside-out
configurations using fire-polished pipettes with a resistance of
20–25 megaohms. The pipette solution contained 140 mM
NaCl, 5 mM KCl, 1 mMMgCl2, 1 mM CaCl2, and 10 mM HEPES
(pH 7.4), and the bath solution contained 140 mM NaCl, 5 mM
KCl, 1 mMMgCl2, and 10mMHEPES (pH 7.4). Following patch
excision, channels were activated by adding the catalytic sub-
unit of PKA (40 unit/ml; Promega, Madison, WI) and 1 mM
MgATP. After channel activation, EBP50 and/or Shank2-PDZ
at desired concentrations was added to the bath. Holding volt-
age used in the single channel recording was 60 mV. The
pCLAMP software package (version 9.2, Axon Instruments)
was used for data acquisition and analysis. The voltage and
current data were low pass-filtered at 1 kHz during the record-
ings, and the single channel data were further digitally filtered
at 25 Hz. The number of active channels in a patch was deter-
mined from the number of simultaneously open channels dur-
ing at least 15 min of recording.
Reverse Transcription-PCR—Reverse transcription-PCR
analysis was performed to identify the phosphodiesterase
(PDE) isoforms in NIH 3T3 cells and T84 cells using protocols
reported previously (12). The primer sequences specific to
PDE3 and PDE4 were selected from regions common to both
mouse and human PDEs: 1) PDE3A: sense, CAC AGG GCC
TTA ACT TAC AC; antisense, TTG AGT CCA GGT TAT
CCATGAC; PCRproduct, 370 bp; 2) PDE3B: sense, CAGGAA
GGA TTC TCA GTC AGG; antisense, GTC ATT GTA TAA
AAC TGC CTG AGG; PCR product, 464 bp; 3) PDE4A: sense,
ATC AAC ACC AAT TCG GAG C C; antisense, TCA CCC
TGC TGG AAG AAC TC; PCR product, 398 bp; 4) PDE4B:
sense, AGT CCT TGG AAT TGT ATC GG; antisense, CTG
GAT CAA TCA CAC AAA GCG TC; PCR product, 432 bp; 5)
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PDE4C: sense, TTC CAGATCCCAGCAGACAC; antisense,
ATG ACC ATC CTG CGC AGA CTC; PCR product, 392 bp;
and 6) PDE4D: sense, GCC AAG GAA CTA GAA GAT GTG;
antisense, CAT CAT GTA TTG CAC TGG C; PCR product,
328 bp.
Immunoprecipitation (IP), Immunoblotting, and Immuno-
histochemistry—CHO-K1, COS-7, T84 cells, and rat cerebel-
lumwere lysed with lysis buffer (20mMHEPES, pH 7.4, 200mM
NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM NaVO4, and 1 mM
-glycerophosphate) containing Complete protease inhibitor
mixture (Roche Applied Science). After lysis, cell debris were
removed by centrifugation, and cleared lysates weremixedwith
the appropriate antibodies and incubated overnight at 4 °C.
Immune complexes were collected by incubation for 2 h at 4 °C
with protein A/G PLUS-agarose and washed four times with
lysis buffer prior to electrophoresis. The immunoprecipitates
and cell lysates were suspended in 2 SDS sample buffer and
boiled for 5 min and then separated by SDS-PAGE. The sepa-
rated proteins were transferred to nitrocellulose membranes,
and the membranes were blocked by incubation for 1 h in a
solution containing 5% nonfat dry milk in 20 mM Tris-HCl, pH
7.5, 150 mM NaCl, and 0.05% Tween 20. The membranes were
then incubated with the appropriate primary and secondary
antibodies, and protein bands were detected with enhanced
chemiluminescence solutions. Rabbit polyclonal antibodies
anti-Shank2 1136 (17) and anti-PDE4D5 -4D5 (18) and the
mouse monoclonal pan-PDE4D antibody M3S1 (20) were
described previously. Rabbit polyclonal pan-PDE4D antibody
ab14613 was purchased from Abcam Inc., Cambridge, UK.
Immunostaining of frozen sections was performed as
reported previously (12). Briefly colon tissues from Sprague-
Dawley rats were embedded in OCT (Miles, Elkhart, IN),
frozen in liquid N2, and cut into 4-m sections. The sections
were stained by incubation with polyclonal anti-Shank2
1136 and monoclonal anti-pan-PDE4DM3S1 antibodies fol-
lowed by appropriate secondary antibodies tagged with flu-
orophores. Images were obtained with a Zeiss LSM 510 con-
focal microscope.
GST Pulldown Assay—Regions corresponding to residues of
rShank2PDZ-(1–142), proline-rich (PR)-(134–1176), and ster-
ile  motif-(1164–1253) domains were PCR-amplified and
cloned into pGEX-4T-1 vector (AmershamBiosciences) to cre-
ate GST fusion constructs. Shank2 PR domains were further
dissected, and twoGST fusion constructs were generated: PR1-
(134–669) and PR2-(647–1176). All fusion proteins were
expressed in E. coli BL21 (DE3) and purified with glutathione-
Sepharose 4B (Amersham Biosciences). For pulldown assays,
CHO cells were lysed on ice in a 1% Triton X-100 buffer con-
taining 150mMNaCl, 2mMMgCl2, 2mMCaCl2, 10mMHEPES,
pH 7.4, and proteinase inhibitors (CompleteMini, Roche
Applied Science). Debris was removed by centrifugation, and
100l of lysate supernatants were supplemented with 900l of
buffer prior to addition of 10 g of each GST fusion protein.
Following overnight incubation at 4 °C, samples were supple-
mented with 80 l of glutathione-Sepharose (Amersham Bio-
sciences) and incubated for an additional 4 h at 4 °C. The glu-
tathione-Sepharosewas pelleted andwashed (3 5min) at 4 °C
with wash buffer (phosphate-buffered saline containing 0.1%
Triton X-100 and 100 mM -mercaptoethanol) prior to resus-
pension in SDS sample buffer and SDS-PAGE.
Measurements of PDE Activity—Whole brain tissues from
wild type and PDE4D knock-out mice (21) were lysed in buffer
containing 50 mM HEPES, pH 7.4, 250 mM NaCl, 10% glycerol,
0.5%Nonidet P-40, 1mM EDTA, 0.2mM EGTA, 10mMNaF, 10
mMNa4P2O7, 1Mmicrocystin, 2mM 4-(2-aminoethyl) benze-
nesulfonylfluoride, and a mixture of protease inhibitors. Cell
lysates were centrifuged at 14,000  g, and supernatants were
immunoprecipitated using 5 l of anti-Shank2 antibody cou-
pled to 25 l of protein G-Sepharose for 4 h. After centrifuga-
tion, pelletswerewashed three times, andPDEactivitywas then
measured as described previously (18). In brief, samples were
assayed in a reaction mixture of 200 l containing 40 mM Tris-
HCl, pH 8.0, 10 mM MgCl2, 5 mM -mercaptoethanol, 1 M
cAMP, 0.75 mg/ml bovine serum albumin, and 0.1 Ci of
[3H]cAMP for 10 min at 33 °C. The reaction was terminated by
the addition of 200 l of 10 mM EDTA in 40 mM Tris-HCl, pH
8.0, followed by heat inactivation in a boiling water bath for 1
min. The PDE reaction product 5-AMP was then hydrolyzed
by incubation of the assay mixture with 50g ofCrotalus atrox
snake venom for 20 min at 33 °C. The resulting adenosine was
separated by anion exchange chromatography using 1 ml of
AG1-X8 resin and quantitated by scintillation counting.
RESULTS
Shank2 and EBP50 Compete for Binding on CFTR—To
understand the dynamics of CFTR positive and negative regu-
lations, we determined the binding kinetics of the association
between CFTR and the PDZ domains of EBP50 and Shank2
using SPR analyses (Fig. 1). As EBP50 has two PDZ domains,
three His-tagged proteins, PDZ1-(1–139), PDZ2-(132–299),
and PDZ12-(1–299), were used to analyze their kinetics sep-
arately. His-tagged PDZ domains were captured onNTA chips,
and their binding to the GST-tagged C terminus of CFTR was
sensored by SPR. As shown in the sensorgrams, the PDZ
domains of Shank2 and EBP50 specifically bind the C terminus
of CFTR in a dose-dependent fashion (Fig. 1, A and B). The
overall dissociation constants at the equilibrium state (KD val-
ues) of Shank2 PDZ and EBP50 PDZ12 were within compa-
rable ranges at the tens of nanomolar levels (Fig. 1C). Interest-
ingly EBP50 PDZ12 has approximately a 1 order of
magnitude faster association (Ka) and dissociation (Kd) kinetics
than Shank2 PDZ. Further analyses of EBP50 PDZs using sep-
arate PDZ1 and PDZ2 proteins revealed that the overall EBP50
binding to CFTR is driven by PDZ1, which has a 3 times
higher affinity than PDZ2 (Fig. 1C). A solution competition
assay was performed to examine the possibility of mutual com-
petition between the PDZs of Shank2 and EBP50 in binding to
CFTR. After capturing His-tagged Shank2 PDZ on NTA chips,
the SPR systemwas perfusedwith a fixed dose of theC terminus
of CFTR (300 nM) and increasing doses of GST-tagged EBP50
PDZ12. Importantly the addition of EBP50 PDZs dose-de-
pendently decreased the association between Shank2 PDZ and
CFTR with an IC50 value of 91 nM (Fig. 1D).
Regulation of CFTR Cl Channel Activity by CFTR-EBP50
andCFTR-Shank2Competitions—The above results imply that
Shank2 and EBP50 compete for binding on CFTR. This com-
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petitive balance may affect CFTR ion transporting activities at
the apical membrane of intestine, pancreas, and kidney epithe-
lia, where Shank2 and EBP50 are abundantly expressed (7, 12).
We therefore determined the effects of the competition
between EBP50 and Shank2 PDZ binding on the CFTR Cl
channel activity using inside-out configurations (Fig. 2). Fol-
lowing patch excision fromCFTR-transfectedCHOcells, patch
membranes were washed with a high bath flow for 5 min to
eliminate endogenous activation.WhenCFTRwas activated by
the addition of the catalytic subunit of PKAandATP to the bath
solution, an ion channel activity with a single channel conduct-
ance of 7.1 0.3 picosiemens and a linear current-voltage rela-
tionship was evoked that was absent in mock-transfected cells.
It has been shown that adaptors with multiple PDZ domains,
such as EBP50 and CAP70/PDZK1, can activate CFTR Cl
channel activity independently of cAMP signals by altering pro-
tein conformation includingmultimerization (23, 24). In agree-
ment with these reports, treatment with EBP50 (100 nM)
induced a 2.8-fold increase in the open probability (Po) of
CFTR. Importantly addition of Shank2 PDZ (300 nM) inhibited
the EBP50-induced increase in CFTR Po by 75  8% (Fig. 2, A
and C). The effect of Shank2 PDZ versus EBP50 competition
was then examined in reverse order. Shank2 PDZ treatment
alone did not evoke significant changes in CFTR Po at basal
levels; however, it greatly inhibited the CFTR activation medi-
ated by EBP50. Addition of EBP50 induced only a minor
increase in CFTR Po after Shank2 pretreatment (Fig. 2, B and
D). When performing the above experiments using EBP50
PDZ12, which does not bind AKAPs due to the lack of the
ezrin-radixin-mosesin (ERM) domain, we obtained results sim-
ilar to those using the entire EBP50 protein (Fig. 2, C and D).
These findings indicate that Shank2 can reversibly inhibit the
EBP50-induced CFTR activation by competing with EBP50 for
binding at the C terminus of CFTR and hence by breaching the
EBP50-induced active conformation of CFTR. However, this
does not explain the observation that Shank2 inhibits the
cAMP-induced phosphorylation and activation of CFTR in liv-
ing cells. In CFTR-expressing NIH 3T3 cells, it has been shown
that Shank2 overexpression decreased CFTR channel activity
and phosphorylation induced by the adenylyl cyclase activator
forskolin (12). It is well known that CFTR is primarily activated
by phosphorylation of the R-domain by PKA (2). Recruitment
FIGURE 1. Interactions between CFTR and PDZ-based adaptors determined by SPR assays. A and B, sensorgrams showing the interaction between the C
terminus of CFTR and the PDZdomains of Shank2 and EBP50/NHERF1. His-taggedPDZdomains of Shank2 and EBP50were capturedonNTA chips,whichwere
then perfused with various concentrations of a peptide encoding the C-terminal 29 amino acids of CFTR. C, binding kinetics of the interaction between CFTR
and the PDZ domains of Shank2 and EBP50. Values shown represent the average of two experiments each performed in duplicate.D, sensorgramof a solution
competition assay between CFTR-Shank2 PDZ and CFTR-EBP50 PDZ12 interactions. After capturing His-tagged Shank2 PDZ, the NTA chips were perfused
with a fixed concentration of the C terminus of CFTR (300 nM) and increasing concentrations of the GST-tagged EBP50 PDZ12. EBP50 PDZ12 dose-depend-
ently decreased the CFTR-Shank2 PDZ associationwith an IC50 value of 91 nM (n 3). Ka, association constant; Kd, dissociation constant; KD, overall dissociation
constant at equilibrium status (Kd/Ka).
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by Shank2 of cyclic nucleotide PDEs, which attenuate cAMP
signals, or phosphatases, which offset the action of PKA, might
explain these findings. The latter is unlikely, however, because
CFTR phosphorylation was decreased in the Shank2-trans-
fected cells even in the presence of a high concentration of the
nonspecific phosphatase inhibitor NaVO4 (12).
Shank2 Associates with PDE4D—An important clue was
obtained in an experimentwith the non-selective PDE inhibitor
IBMX (Fig. 3, A–D). Stimulation of CFTR-expressing CHO
cells with 3 M forskolin induced a CFTR Cl current that is
dependent on the presence of Cl in bath and pipette solutions,
is inhibited by 5-nitro-2-(3-phenylpropylamino)benzoate, and
has linear current-voltage relationships in whole-cell configu-
rations. However, when Shank2 was co-expressed, the same
amount of forskolin produced very small or no CFTR currents.
Interestingly additional treatment with IBMX evoked a robust
CFTR current in Shank2-expressing cells, although its peak
amplitude was still 56 7% that of mock-transfected cells (Fig.
3, A and B).
These results suggest a functional association between the
PDE activity and the Shank2-mediated inhibition of CFTR.We
next identified the PDE subtypes involved and determined
whether Shank2 directly interacts with PDEs. Of the 11 PDE
families, PDE3 and PDE4 are strong candidates for Shank2
association as they are sensitive to IBMX and are known to be
expressed in epithelial cells (25). The PDE3 family consists of
two genes, 3A and 3B, and the PDE4 family consists of four,
4A–4D. Reverse transcription-PCR results using primers spe-
cific to the common regions of mouse and human PDEs
revealed that several PDE3 and PDE4 genes, including PDE3A,
-4A, and -4D, are expressed in mouse fibroblast NIH 3T3 cells
and human colonic T84 cells (Fig. 3E). As both PDE3 and PDE4
are expressed, the patch clamp experiment shown in Fig. 3B
was repeated after pretreatment of the cells with the PDE3-
specific inhibitor trequinsin and the PDE4-specific inhibitor
rolipram (Fig. 3, C and D). PDE3 inhibition did not alter the
effects of Shank2 (Fig. 3C). Conversely when PDE4 was inhib-
ited by rolipram, 3 M forskolin consistently induced a robust
CFTR current in Shank2-expressing cells (Fig. 3D, n  5),
strongly suggesting an association between Shank2 and PDE4
isoforms. Recently two reports suggested that PDE4D plays a
major role in forming a cAMP diffusion barrier at the apical
regions of epithelial cells (22, 26). Consistent with this notion,
expression of PDE4D proteins was observed in the immunob-
FIGURE 2. Regulation of CFTR single channel activity by a competition between CFTR-EBP50 and CFTR-Shank2 PDZ binding. CFTR Cl channel activity
wasmeasured in CFTR-transfectedCHOcellswith inside-out configurations. Current records at60mVwere analyzed to estimate the Po.A, after a 5-minwash
of patchmembranes, CFTRwas activated by addition of PKA. Solutions containing EBP50 (100 nM)with andwithout Shank2 PDZ (300 nM)were perfused to the
bath chamber at 5-min intervals. Powas calculated from the recording of the last 1min of each 5-min interval. Similar experimentswere performedwith EBP50
PDZ12, which lacks the AKAP/PKA-binding ezrin-radixin-moesin (ERM) domain, instead of EBP50 (whole). A summary of five experiments with EBP50 and
three experiments with EBP50 PDZ12 is presented in C. B, the effect of Shank2 PDZ and EBP50 binding on CFTR activity was examined in reverse order of A
with Shank2 PDZ treatment preceding the EBP50 treatment. A summary of five experiments with EBP50 and three experiments with EBP50 PDZ12 is
presented in D. O, open; C, closed.
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lots of NIH 3T3, CHO, and T84 cells (Fig. 3F) in which the
inhibitory effects of Shank2 on cAMP/PKA signals were dem-
onstrated in this and previous studies (11, 12).
To probe for a physical association between Shank2 and
PDE4D, co-IPs were performed. Human and rat PDE4D loci
have multiple transcriptional units that code for at least nine
splice variants, PDE4D1 to PDE4D9 (18). Among them,
PDE4D5 has been shown to be expressed in epithelial cells and
to mediate cAMP hydrolysis at the apical microdomain (22).
Thus, Shank2 and the PDE4D splice variant PDE4D5 were
overexpressed in CHO cells followed by IP with antibodies
against Shank2 and PDE4D5 (Fig. 3G). Shank2 proteins were
observed in immunoprecipitates with PDE4D5-specific anti-
bodies. In a converse experiment, PDE4D5 could be detected in
Shank2 immunoprecipitates. These co-IPs were specific as they
could only be detected in cells expressing both Shank2 and
PDE4D5 (Fig. 3G).
To identify its PDE4D-binding domain, several truncated
Shank2 constructs were generated and used for pulldown
assays. Shank2 has multiple sites for possible protein-protein
interactions, including a PDZ domain, a long PR region, and a
sterile  motif domain (27). The PR region contains five pro-
line-rich clusters, including a cortactin-binding domain (ppI)
(28). In initial pulldown assays using the lysates from the
PDE4D5-transfected CHO cells, PDE4D5 showed an interac-
tion with the PR region of Shank2 (Fig. 4B, left). The PR region
was then further dissected into two parts, PR1 and PR2, and the
PDE4D binding site was mapped to the PR2 region (Fig. 4B,
right) where three proline-rich clusters and a ppI are clustered
(Fig. 4A).
Next all PDE4D splice variants were co-immunoprecipitated
with Shank2 to identify the PDE4D variants that interact
with Shank2 and to identify the putative Shank2 binding site
in PDE4D. COS-7 cells were transfected with plasmids
encoding Shank2 and the nine PDE4D splice variants,
PDE4D1 to PDE4D9, followed by immunoprecipitation
using the pan-PDE4D antibodyM3S1. All PDE4D long forms
(D3, D4, D5, D7, D8, and D9) were found to interact with
Shank2, whereas the short forms, D2 and D6, do not (Fig.
4D). A weak interaction was detected in the case of PDE4D1.
The PDE4D splice variants are distinguished by the presence
or absence of two conserved N-terminal domains called
upstream conserved regions 1 and 2 (UCR1 and UCR2; Fig.
4C). The above results imply that UCR1 and the N-terminal
part of UCR2 mediate Shank2 binding.
Shank2 and PDE4D Associate in Vivo—The association
between Shank2 and PDE4D was then examined in cells that
natively express both proteins to explore its physiological role.
FIGURE 3. Shank2 associates with PDE4D. A–D, CFTR Cl channel activity at whole-cell configurations was measured in CFTR-expressing CHO cells with or
without Shank2 co-transfection. Treatmentwith forskolin (3M) evoked a largeCl current inmock-transfected cells (A) but not in Shank2-transfected cells (B).
CFTR currents in Shank2-transfected cells were restored by treatment with the non-selective PDE inhibitor IBMX (B) or the PDE4-specific inhibitor rolipram (D)
but notwith the PDE3-specific inhibitor trequinsin (C). E, detection of PDE3 and PDE4 isoforms in NIH 3T3 cells (mouse fibroblast) and T84 cells (human colonic
epithelia) by reverse transcription-PCR (RT-PCR). Primer sequences specific to PDE3 andPDE4 isoformswere selected from the regions common tobothmouse
and human PDEs. Lane M, molecular weight markers. F, expression of PDE4D proteins in NIH 3T3, CHO, and T84 cells was analyzed by immunoblotting using
rabbit polyclonal pan-PDE4D antibody. G, Shank2 (Sh2) and the PDE4D splice variant PDE4D5 (4D5) were overexpressed in CHO cells (upper panels) and
subsequently immunoprecipitated from cell extracts using anti-PDE4D5 and anti-Shank2 antibodies (lower panels). IB, immunoblot.
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Initially we investigated the expression of Shank2 and PDE4D
in rat colonic mucosa. Shank2 and PDE4D were highly co-lo-
calized at the apical region of colonic crypt cells, where CFTR
plays a major role in fluid and ion secretion (Fig. 5A). The
Shank2-PDE4D interaction was also verified by immunopre-
cipitation of the endogenous proteins prepared from T84
human colonic epithelial cells. It is well known that PDE4 can
be activated by PKA-induced phosphorylation of UCR1 (29).
Interestingly stimulation of the cAMP/PKA pathway using the
adenylyl cyclase activator forskolin increased the physical asso-
ciation between Shank2 and PDE4D in T84 cells (Fig. 5B).
Finally the Shank2-PDE4D interaction was examined in
mouse brain tissues where multiple PDE isoforms as well as
Shank2 are expressed at high levels. In immunoprecipitates
using pan-PDE4D antibodies, multiple Shank2-immunoreac-
tive bands were detected in addition to the typical 170-kDa
Shank2 (Fig. 5C) due to the presence of distinct Shank2 splice
variants in brain tissue (17, 28). Mouse brain tissue was then
immunoprecipitated with anti-Shank2 antibodies, and the
resulting IP pellets were subjected to PDE activity assays. The
PDE activity co-immunoprecipitating with Shank2 was inhib-
ited by the PDE4-selective inhibitor rolipram (Fig. 5D). In addi-
tion, the co-immunoprecipitation of PDE was ablated in IPs
using tissue from PDE4D knock-out mice (Fig. 5E) indicating
that Shank2 specifically interacts with PDE4D in mouse brain
tissue.
DISCUSSION
In the present study, we provide comprehensive evidence
that the activity of CFTR is dynamically regulated by a compet-
itive balance between CFTR-activating and CFTR-inactivating
PDZ domain interactions. In addition, activity of Shank2, the
CFTR-inactivating PDZ adaptor, was found to be associated
with PDE4D, which precludes cAMP/PKA signals. The regula-
tory mechanisms resulting from the association of CFTR with
EBP50 and Shank2 are summarized in Fig. 6. It is known that
EBP50 can activate CFTR through two independent mecha-
nisms. First, EBP50 can recruit ezrin, a PKA-anchoring protein,
and hence facilitates the cAMP/PKA-mediated phosphoryla-
tion of CFTR (7). Second, EBP50 can activate CFTR by confor-
mational changes, possibly by forming a CFTR dimer (23). The
results of this study revealed that Shank2 can inhibit both
mechanisms by competing with EBP50 at the C terminus of
CFTR. The finding that Shank2 inhibited the EBP50-induced
FIGURE 4. Domains responsible for the association between Shank2 and PDE4D. A and B, to identify the PDE4D-binding domain of Shank2, pulldown
assays were performed using GST fusion proteins containing different domains of Shank2 and PDE4D expressed in CHO cells. Domain structures of the GST
fusion proteins are illustrated in A, and pulldown results are shown in B. Lysates from rPDE4D5-transfected CHO cells were pulled down with GST-tagged
Shank2 fragments and blotted with anti-PDE4D5 antibody. C and D, immunoprecipitation of Shank2 with the nine PDE4D splice variants. COS-7 cells were
transfected with plasmids encoding Shank2 and the PDE4D splice variants, PDE4D1 to PDE4D9 (D1–D9). After 3 days of culture, cells were harvested, and the
resulting detergent extracts were subjected to IP with the pan-PDE4D antibodyM3S1. The domain structures of PDE4D splice variants are illustrated in C, and
IP results are presented in D. PRCs, proline-rich clusters; SAM, sterile motif; IB, immunoblot.
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increase ofCFTRPo in inside-out patches (Fig. 2) demonstrated
that Shank2 can antagonize the EBP50 function by breaching
the EBP50-induced active conformation of CFTR independ-
ently of cAMP signals. Even more interesting, this study shows
that Shank2 can ablate cAMP signaling in the vicinity of the
CFTR by tethering PDE4D into this macromolecular complex.
It is well known that cAMP signals are compartmentalized in
many cell types and that localized cAMP signals play a critical
role in various physiological processes (29). For example, local-
ized cAMP accumulation in a region overlapping with the Z
band and the T tubules in cardiomyocytes is essential for the
regulation of cardiac myocyte contraction by -adrenergic
receptors (30). Several recent reports underscored the impor-
tance of PDE4D as a cAMP diffusion barrier formed at the api-
cal membrane of epithelia for the proper functioning of CFTR
(22, 26). However, themolecularmechanisms for PDE accumu-
lation in apical regions remained obscure. A thorough molecu-
lar characterization in this study revealed that the apical adap-
tor Shank2 recruits PDE4D through a direct interaction
between the proline-rich region of Shank2 and the UCR1/2
region of PDE4D. The proximal localization of cAMP regulat-
ing machinery will induce an increased signaling efficiency in
regulating CFTR activity. Recently Shank2E, a splice variant of
Shank2 with additional ankyrin repeats and a Src homology 3
domain, was identified in epithelial cells (31). Therefore, we
FIGURE5.Shank2andPDE4Dassociate in vivo.A, immunolocalizationof Shank2andPDE4D in rat colonwasdetectedusingpolyclonal anti-Shank2antibody
1136andmonoclonal pan-PDE4DantibodyM3S1. Shank2andPDE4Dwereco-localized in theapical regionofcoloniccryptcells.B, co-IPofShank2andPDE4Dfrom
extracts of human colonic T84 cells. Forskolin treatment (10M for 30min) enhanced the associationbetweenShank2 andPDE4D.C, detectionof Shank2proteins in
PDE4Dimmunoprecipitates frommousebrain.DandE,measurementofPDEactivity inShank2 immunoprecipitates frommousebrain. InD, PDEactivity inShank2 IPs
fromwild typemicewasdetermined in thepresenceor absenceof the PDE4-specific inhibitor rolipram (10M). In E, PDE activity in immunoprecipitates fromPDE4D
wild typemice (PDE4D-WT) is comparedwith immunoprecipitates fromPDE4D knock-outmice (PDE4D-KO). Ab, antibody; IB, immunoblot.
FIGURE 6. A model for the regulation of CFTR through interaction with
EBP50 and Shank2. Through their respective PDZ domains, Shank2 and
EBP50 compete for binding of the CFTR C terminus. Binding of EBP50 acti-
vates CFTR through a conformational change. In addition, EBP50 facilitates
the PKA-mediated phosphorylation and activation of CFTR by bringing the
AKAP ezrin and PKA into the protein complex. Shank2 inhibits CFTR activity
by breaching the CFTR-EBP50 association and by bringing PDE4D,which pre-
cludes cAMP/PKA signaling, closer to CFTR. SAM, sterile  motif; R of CFTR,
R-domain; R and C of PKA, regulatory and catalytic subunits.
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repeated the experiments in Fig. 3 with Shank2E. The results
were nearly identical to those obtained using Shank2 suggesting
that domains within the structure of Shank2 are important for
regulating CFTR function (data not shown).
The physiological significance of the Shank2-PDE4D associ-
ation is not confined to epithelial cells but can be extended to
other organs. For example, Shank2 is widely expressed in many
regions of the brain including cortex, hippocampus, and cere-
bellum. Shank proteins are the key organizer of PSD and inter-
actwithHomer (27, 32), which is required for efficient signaling
of metabotropic glutamate receptors that play a critical role in
learning and memory. Effector systems of metabotropic gluta-
mate receptors are not only associated with Ca2 signaling but
also with cAMP signals, and it is believed that cAMP signals
play a role in the functional specificity of each metabotropic
glutamate receptor isoform (33, 34). Therefore, Shank2-associ-
ated PDE4Dmay play a critical role in the regulation of PSD in
neuronal cells.
Recent studies with knock-out animals of NHERF family
PDZ proteins (EBP50, E3KARP, and PDZK1) have shown that
the functions of these adaptors are more complex than previ-
ously appreciated and appear to be tissue-specific (6). Because
PDZ domains have well defined binding sites, they are promis-
ing targets for drug discovery. However, as the present study
demonstrates, much is yet to be learned about the function of
each PDZ-based adaptor before drugs targeting PDZ interac-
tions can become a reality (35). For example, as the PDZ struc-
tures of EBP50 and Shank2 are very similar, small molecules or
peptides targeting EBP50 may have untoward effects in vivo by
disrupting Shank2 complexes as well.
In conclusion, the present study demonstrates the functional
diversity of PDZ-mediated protein-protein interactions and
illustrates that opposite signals can be delivered to the same
PDZ-binding motif of a given membrane protein by different
adaptors. A competitive balance between the signal-conferring
and signal-stopping PDZ interactions would be critical in the
regulation of many membrane transporters and receptors as
demonstrated here for CFTR.
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